Recurrence of colorectal cancer and perioperative blood transfusion
- 1 February 1990
- journal article
- Published by Wolters Kluwer Health in Diseases of the Colon & Rectum
- Vol. 33 (2) , 127-130
- https://doi.org/10.1007/bf02055541
Abstract
In a prospective study of 35 patients undergoing surgery for colorectal cancer, the mitogenic activity of plasma was measured using 3T3 Swiss fibroblasts as target cells. Transfused patients exhibited a 100 percent increase in mitogenic activity over preoperative values compared with no significant change in nontransfused patients. Samples were taken from blood during 28 days of storage following donation, and mitogenic activity measured. The mitogenic activity increased with storage time, the principal changes occurring from the end of the second week. The increased mitogenic activity in patients following transfusion and in stored blood may be a factor in the mediation of the deleterious effect of transfusion on recurrence in colorectal cancer and perhaps "fresh" blood, if required, should be used.Keywords
This publication has 12 references indexed in Scilit:
- Enhanced growth of artificial tumor metastases following blood transfusion: The effect of erythrocytes, leukocytes and plasma transfusionEuropean Journal of Cancer and Clinical Oncology, 1987
- Effect of pre-operative blood transfusion on tumour metastasesBritish Journal of Surgery, 1987
- Effect of perioperative blood transfusion on recurrence of colorectal cancerBritish Journal of Surgery, 1986
- Association between transfusion of whole blood and recurrence of cancer.BMJ, 1986
- Relation between cancer of the colon and blood transfusion.BMJ, 1985
- Perioperative Allogeneic Blood TransfusionsArchives of Surgery, 1985
- Relation between recurrence of cancer of the colon and blood transfusion.BMJ, 1985
- Adverse relationship between blood transfusions and survival after colectomy for colon cancerCancer, 1985
- EFFECT OF BLOOD TRANSFUSIONS ON COLONIC MALIGNANCY RECURRENCE RATEThe Lancet, 1982
- The case history of Mr T.I. Terminal patient or still curable?Immunology Today, 1980